Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus BCG versus BCG alone in high-risk BCG-naive non-muscle-invasive bladder cancer
NL-OMON50693Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab, bcg vaccine in non-muscle-invasive bladder cancer (NMIBC), bladder cancer, sponsored by AstraZeneca. Started May 2019; status: recruiting.
02
Drugs
durvalumabbcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)bladder cancer
Beyond the preview
Go deeper on NL-OMON50693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50693.